The high RCY, excellent RCP, good biocompatibility, high stability, and specific ER-targeting ability suggested that the radiotracer [18F]AmBF3-TEG-ES might be a promising PET imaging agent for diagnosis of ER+ breast cancers. This evidence concerns the gene ESR1 and breast cancer.